Pfizer Cancer Drug Fails Phase 3 Study, Raising Questions Over Seagen Deal

Key Facts

In a move that highlights the high-risk nature of biopharmaceutical development, Pfizer reported disappointing clinical results from its oncology pipeline. The experimental drug sigvotatug vedotin, acquired through the company's massive Seagen acquisition, failed to meet its overall survival goal in a Phase 3 lung cancer study. According to reports, the drug did not significantly extend survival compared to standard chemotherapy, raising concerns regarding the long-term valuation and revenue contributions of the Seagen deal.

This clinical setback follows Pfizer's $43 billion acquisition of Seagen, a strategic pivot intended to bolster its cancer portfolio as COVID-19 product revenues decline. In contrast to peers, Pfizer faces stiff competition as AstraZeneca has recently secured regulatory wins for similar lung cancer therapies, per market data. Analysts suggest this failure could weigh on the overall deal's ROI, although the company continues to explore the drug's potential in ongoing combination trials.

Regarding market performance, PFE shares stood at $25.21 (close June 18, 2026), trading within a range of $24.94 to $25.66 during the session. Investors are now looking for management commentary on alternative R&D catalysts. Additionally, the market is monitoring broader economic indicators such as US Retail Sales, which grew by 0.7% in June per the economic calendar, for their impact on healthcare sector sentiment.